D. Boral Capital Reaffirms Buy Rating for Can-Fite BioPharma (NYSE:CANF)

Can-Fite BioPharma (NYSE:CANF)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $10.00 price target on the stock.

Separately, StockNews.com initiated coverage on Can-Fite BioPharma in a research note on Tuesday, April 8th. They issued a “sell” rating for the company.

Can-Fite BioPharma Stock Performance

Shares of NYSE CANF opened at $1.23 on Tuesday. The firm’s 50 day moving average price is $1.56 and its 200 day moving average price is $1.77. The firm has a market cap of $4.35 million, a P/E ratio of -0.69 and a beta of 1.37. Can-Fite BioPharma has a 1 year low of $1.18 and a 1 year high of $4.69.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. BNP Paribas Financial Markets bought a new position in Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned 0.71% of Can-Fite BioPharma at the end of the most recent quarter. 21.00% of the stock is owned by institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.